GHK-Cu vs Cortagen

GHK-Cu and Cortagen represent fundamentally different classes of research peptides. GHK-Cu is a naturally occurring copper-bound tripeptide with a robust, multi‑decade evidence base spanning wound healing, dermatology, and gene expression modulation. Cortagen (Ala‑Glu‑Asp‑Leu) is a synthetic tetrapeptide developed within the Khavinson bioregulator framework, proposed to normalize cerebral cortex gene expression. The core distinction lies in evidence maturity and mechanistic specificity: GHK-Cu benefits from independent replication and clinical safety data, while Cortagen relies on preclinical Russian studies and small observational reports. Researchers must weigh these factors when designing studies focused on skin regeneration, neuroprotection, or systemic anti-aging mechanisms.

GHK-Cu (glycyl‑L‑histidyl‑L‑lysine copper complex, MW ~340 g/mol) was discovered by Dr. Loren Pickart in 1973 as a naturally occurring plasma peptide. Its concentrations decline with age—from ~200 ng/mL at age 20 to ~80 ng/mL by age 60—suggesting a physiological role in tissue maintenance. Mechanistically, GHK-Cu binds copper and modulates over 4,000 human genes, including those involved in collagen synthesis, antioxidant defense, and DNA repair. Preclinical models demonstrate accelerated wound healing, increased angiogenesis, and improved skin elasticity. Clinical evidence, including controlled trials and decades of cosmetic use, supports its safety and efficacy in dermal repair. The mechanism is copper‑dependent: GHK acts as a copper transporter, facilitating enzymatic activities of superoxide dismutase and lysyl oxidase. This well‑characterized pathway underpins its broad research utility in aging, wound care, and dermatology.

Cortagen (Ala‑Glu‑Asp‑Leu, MW ~446 g/mol) is a synthetic tetrapeptide designed by Vladimir Khavinson as a bioregulator for cerebral cortex tissues. The proposed mechanism involves epigenetic normalization: Cortagen is thought to bind DNA regulatory regions and restore age‑related declines in gene expression specific to cortical neurons. Evidence derives predominantly from Russian preclinical ischemia models and small, uncontrolled clinical observations. These reports suggest improvements in cognitive function and reduced neuronal loss after stroke, but no independent replication or placebo‑controlled trials have been published. The peptide’s short sequence and lack of metal‑binding activity contrast sharply with GHK-Cu’s copper‑dependent signaling. Researchers should note that Cortagen remains at an early investigative stage, with significant gaps in pharmacokinetic data, dose‑response characterization, and mechanistic validation beyond the Khavinson laboratory.

Despite both being investigated for anti‑aging, GHK-Cu and Cortagen occupy almost entirely distinct research niches with minimal overlap. GHK-Cu’s research focus centers on skin health, wound healing, and extracellular matrix remodeling—applications where its copper‑dependent gene modulation is directly relevant. Cortagen, by contrast, is exclusively studied in neuroprotection, cognitive decline, and post‑ischemic recovery, with no reported dermatological use. The overlap in “anti‑aging research” is thematic rather than mechanistic; GHK-Cu targets systemic tissue maintenance, while Cortagen aims at cortical resilience. For researchers, the selection criterion is straightforward: choose GHK-Cu for studies involving dermal repair, copper metabolism, or general aging biomarkers; choose Cortagen only if the specific hypothesis involves cortical gene regulation and the investigator accepts the limitations of a nascent evidence base. No combined or synergistic studies have been reported.

GHK-Cu’s safety is supported by extensive clinical and preclinical data. Topical formulations are well tolerated; rare mild irritation occurs only in hypersensitive individuals. Injectable use may produce transient injection‑site reactions, lightheadedness, or nausea, and rotating sites reduces local discomfort. A systematic review (PMID: 29986520) confirms its favorable profile. Cortagen’s safety data, however, are limited to Russian open‑label observations with no controlled toxicology or pharmacokinetic studies. No serious adverse events were reported in those studies, but long‑term safety remains unknown. Direct comparative safety evaluation is impossible due to Cortagen’s evidence gaps. Researchers should prioritize GHK-Cu when safety documentation is critical; Cortagen requires explicit risk acknowledgment and ethical justification in study designs, particularly for chronic administration or vulnerable populations.